KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

ARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company's non-voting convertible preferred stock. KALA received $1.8 million in the first of two closings under the agreement. Effective immediately, Mr. Lazar has been appointed KALA's Chief Executive Officer and Chairman of the Board. Former Chief Executive Officer Todd Bazemore continues to serve on the Board.

Read more at globenewswire.com